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Objective: To predict immunogenic promiscuous T cell epitopes from the polyprotein of
the Zika virus using a range of bioinformatics tools. To date, no epitope data are available
for the Zika virus in the IEDB database.
Methods: We retrieved nearly 54 full length polyprotein sequences of the Zika virus
from the NCBI database belonging to different outbreaks. A consensus sequence was then
used to predict the promiscuous T cell epitopes that bind MHC 1 and MHC II alleles
using PorPred1 and ProPred immunoinformatic algorithms respectively. The antigenicity
predicted score was also calculated for each predicted epitope using the VaxiJen 2.0 tool.
Results: By using ProPred1, 23 antigenic epitopes for HLA class I and 48 antigenic
epitopes for HLA class II were predicted from the consensus polyprotein sequence of
Zika virus. The greatest number of MHC class I binding epitopes were projected within
the NS5 (21%), followed by Envelope (17%). For MHC class II, greatest number of
predicted epitopes were in NS5 (19%) followed by the Envelope, NS1 and NS2 (17%
each). A variety of epitopes with good binding afﬁnity, promiscuity and antigenicity were
predicted for both the HLA classes.
Conclusion: The predicted conserved promiscuous T-cell epitopes examined in this
study were reported for the ﬁrst time and will contribute to the imminent design of Zika
virus vaccine candidates, which will be able to induce a broad range of immune responses
in a heterogeneous HLA population. However, our results can be veriﬁed and employed
in future efﬁcacious vaccine formulations only after successful experimental studies.1. Introduction
Zika virus is a single stranded RNA virus belonged to Fla-
viviridae family [1]. The genome of the virus is 10794
nucleotides long, which is translated into 3410 amino acids
[2]. The large polypeptide chain that is encoded by long and
single ORF is cleaved into: Envelope, a membrane precursor,
a capsid and non-structural proteins including NS1, NS2A,
NS2B, NS3, NS4A, 2K, NS4B, and NS5. The envelope protein
of the virus is involved in the process of fusion of the virus with
the receptor of host cells and is also involved in the replicationcycle of the virus. The NS5 protein has two terminals: N ter-
minus and C terminus, the N terminus has a role in protection of
RNA while the C terminus encodes RNA dependant RPA ac-
tivity [3].
During 1947–2006, more than twenty cases of Zika virus
infection were reported, but the research on them was not given
prime importance because of its geographical spread limited to
the countries in Africa and South Asia, and mild clinical signs
and symptoms of the Zika virus infection [4]. After 2006, a
sudden outbreak of Zika virus was reported in 2007 in the
Yap Island, where 73% of the population was infected with
Zika virus [5]. In 2013 a major outbreak of Zika virus was
reported in the French Polynesia [6]. The infectious Zika virus
then started spreading into the other islands of Paciﬁc Ocean
and in 2014 it arrived in Chile and Eastern island of Western
Hemisphere [7] and in Latin America probably due to infected
travellers. The virus is a mosquito borne virus, and mosquitounder the CC BY-NC-ND license (http://
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humans, which is the primary host of Zika virus. The
transmission of Zika virus is carried out by Aedes species that
includes Aedes albopictus (A. albopictus), Aedes aegypt (A.
aegypt) [8], Aedes luteocephalus (A. luteocephalus), Aedes
furcifer (A. furcifer), Aedes taylori (A. taylori), Aedes
africanus (A. africanus), and monkeys (Rhesus Macaques) [9].
The studies on the transmission of Zika virus show that the
virus can be transmitted through sexual contact [10] due to its
extended persistence in the semen [11], and also through blood
transfusion [12]. Viral load is greater than other arboviruses
and commences about ten days before the clinical
manifestation of the disease [13]. The acute symptoms of Zika
virus infections are arthralgia, maculopapular rash, myalgia,
conjunctivitis, emesis, retro-orbital pain and headache; howev-
er, 80% of the patients are asymptomatic during the initial stages
of infection. Recent reports about the outbreak of Zika virus in
Brazil are linked to microcephaly and Guillain–Barre syndrome
[14]. This association poses serious teratogenic and neuropathic
risks to the health of fetus. A fatal Zika virus infection has
also been reported that shows increased risk of disease and
mortality in individual having compromised immune system
[15].
The infection of Zika virus is fatal and can cause serious
health threatening issues, so an antiviral vaccine or antiviral
therapy needs to be designed in order to control the disease state.
Antiviral therapies need to be designed by targeting enzymes
that are involved in post translational packaging of viral protein
[16] or by targeting enzymes that are essential for the replication
of virus [17]. Development of vaccine for the treatment of Zika
virus is extremely important in current situation as the virus
has caused a great number of deaths in Brazil and is spreading
in the other parts of world. Currently there is no prophylactic
or therapeutic vaccine available in the market to curtail this
infection.
Though the development of live attenuated YFV vaccine was
a milestone but with the new advancements, epitope-based
vaccine are gaining more importance, as the live attenuated
vaccine may prove fatal in immunocompromised patients [18].
Advances in immunoinformatics research found that many
conservative and highly immunogenic T/B cell epitopes (anti-
genic determinants that are recognized by host immune cells and
can elicit both a humoral and cellular immune response) on the
virus antigen could be used as potential vaccine targets. These
epitopes can induce a protective immune response against a
wide range of pathogenic microorganisms. After the artiﬁcial T-
cell epitope is presented via the appropriate MHC molecule on
the surface of the target cell to its corresponding T-cell, the
epitope is recognized by T cells through TCR recognition,
thereby activating the T-cell to proliferate and generate an
appropriate immune response. Based on this scenario, the use of
different pathogenic microorganisms and their corresponding T
cell epitopes can be used to develop a CD4+ T cell epitope
vaccine (mostly for exogenous antigens that are degraded in the
APCs after phagocytosis, thereafter binding to MHC II mole-
cules, and ﬁnally presentation to CD4+ T cells) or a CD8+ T cell
epitope vaccine (mostly for endogenous antigen that are digested
following uptake by the APCs, and subsequent presentation to
CD8+ T cells via MHC-I molecules) [19].
Epitope vaccine or an epitope based subunit-vaccine has
lesser side effects when compared to conventional vaccines, is
easier to produce, is cheaper to manufacture, is easier to get ridof in the in vitro restriction cultures when compared to engi-
neered subunit vaccines, does not contain any complete
component of the pathogens, allows for the in vitro incorpora-
tion of sugar analogs which is difﬁcult to achieve through
engineered subunit vaccines and also takes less time to produce
along with improved stability, speciﬁcity and sustainability [20].
However, due to the highly polymorphic nature of the HLA
genes in the human population, the epitope speciﬁc HLA
restricted vaccine is not normally expected to cause an
immune response in all individuals within a given population.
Thus, there is a need for the development of promiscuous
epitopes that can bind to multiple HLA alleles within a
heterogeneous population thereby catering to the need of a
wide range of individuals [21].
The present study targets the near full length polyprotein of
the Zika virus containing key structural and non-structural pro-
teins, for prediction of promiscuous and antigenic epitopes using
a range of online tools for the development of a safe and
effective epitope based subunit vaccine.
2. Materials and methods
2.1. Sequence retrieval
54 Zika virus polyprotein sequences derived from 54
different genomes were retrieved from the NIAID Virus Path-
ogen Database and Analysis Resource (ViPR) through the web
site at [22] as shown in S1 Table. The sequences were aligned
and consensus sequence was generated using the multiple
sequence alignment tool, Jalview [23].
2.2. Prediction of T cell epitopes
To determine the T cell epitopes, both HLA I and HLA II
binding peptide sequences were required. ProPred I (www.
imtech.res.in/raghava/ProPred1/) [24]was used to predict the
HLA class I binding promiscuous epitopes in the consensus
sequence. 4% default threshold value was selected and
proteasome and immunoproteasome ﬁlters were enabled at 5%
threshold value to maximize the efﬁciency of ﬁnding T cell
epitopes. ProPred I determines epitopes that can bind to 47
HLA class I alleles. To predict epitopes for HLA class II
alleles, ProPred [25] was used at a cut off value of 3%
threshold. ProPred allows the prediction of antigenic epitopes
for 51 HLA class II alleles.
2.3. Antigenic prediction
All the promiscuous T cell epitopes obtained from ProPred
and ProPred1 tools were analysed for their antigenic properties
using VaxiJen version 2.0 at [26]. Threshold value of 0.5
antigenic score was kept to ﬁler probable non-antigenic se-
quences. Moreover, 87% accurate results are obtained for vi-
ruses at this default threshold. Vaxijen server performs
alignment-independent prediction of protective antigens on the
basis of their physicochemical properties.2.4. Class I immunogenicity prediction
All the HLA 1 binding antigenic epitopes were scanned for
MHC 1 immunogenicity using IEDB Analysis tool [27]. Default
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prediction. The tool uses amino acid properties as well as their
position within the peptide to predict the immunogenicity of a
peptide MHC complex.
2.5. Validation of predicted epitopes
The epitopes predicted in our study were submitted to IEDB
database to check if they had been tested earlier. The IEDB
database contains experimentally conﬁrmed data characterizing
antibody and T cell epitopes studied in homo sapiens, NHPs,
and other animal species.
3. Results
3.1. Prediction of HLA I binding epitopes
By using ProPred1, 23 antigenic epitopes for HLA class I
were predicted in the consensus polyprotein sequence of Zika
virus (Table 1). Epitopes were highly conserved across the
different strains of Zika virus. Notably, the promiscuous epitope
NS52592–2600 was found to bind to 26 of the 47 HLA class I
alleles.
Epitope C25–34 was predicted to bind to 18 HLA class I al-
leles. However, its antigenicity score was 0.2434. Hence, that
epitope was not considered for further immunogenicity analysis.
Epitope prM211–219 was predicted to bind to 7 alleles and its
antigenicity score was signiﬁcant i.e. 1.0359.
The overall antigenic prediction of epitope E777–785 was the
highest among the envelope epitope sequences. However, it was
predicted to bind to only 7 HLA class I alleles. Epitopes E706–714
and E757–765 were predicted to bind 12 alleles. However, their
antigenicity scores were below 0.5, indicating that they were
non-antigenic sequences.
NS1897–905 was predicted to bind 18 alleles. However, its
antigenicity score was determined to be signiﬁcantly lowTable 1
T-cell class I MHC-speciﬁc predicted epitopes of the Zika virus polyprotein
genicity score.
Part of polyprotein aa position Epitope sequence
prM 211 RRSRRAVTL
Envelope protein 307 GGTWVDVVL
462 NSPRAEATL
640 QTLTPVGRL
777 MCLALGGVL
NS1 1059 KGPWHSEEL
NS2A 1156 SLGVLVILL
1339 KNLPFVMAL
1355 VDPINVVGL
NS2B 1381 TAVGLICAL
1402 GPMAAVGLL
NS3 1622 DGDIGAVAL
1688 KKQLTVLDL
2018 AAIEGEFKL
NS4A 2177 LGLLGTVSL
2199 KMGFGMVTL
2220 EPARIACVLIVVFLLLVVL
NS4B 2459 WGWGEAGAL
NS5 2520 RGGGTGETL
2592 QPYGKVIDL
2638 SYGWNIVRL
2898 VSSWLWKEL
3065 RFDLENEALi.e. −0.4375. Similarly, NS11017–1025 was predicted to bind 14
alleles but its antigenicity was −0.2001. NS11059–1067 was found
to bind to 13 alleles and its antigenicity was signiﬁcant i.e.
0.8225. Moreover, this epitope was found to be conserved
among all the polyprotein sequences in our study. Hence,
NS11059–1067 was the most suitable epitope identiﬁed in the NS1
of polyprotein.
Similarly, NS2A1339–1347, NS2A1355–1363 and NS2A1156–1164
were identiﬁed as the most signiﬁcant epitopes in the NS2A.
NS2B1402–1410 and NS2B1381–1389 were predicted to bind 14 and
10 HLA class I alleles respectively and their antigenicity score
was found to be signiﬁcant i.e. 0.85.
Epitopes NS32018–2026, NS31622–1630 and NS31688–1696 were
predicted to bind 20, 9 and 6 number of alleles and their anti-
genicity scores were found out to be 1.1351, 1.6507 and
1.5064. Remarkably, all these three epitopes were found to be
completely conserved among all the polyprotein sequences
included in our study.
Similarly, NS4A2199–2207, NS4A2177–2185 and NS4A2220–2238
were predicted to bind 7, 9 and 8 number of HLA class I alleles
and their antigenicity scores were found to be 1.9567, 1.2576
and 0.8174, respectively. However, the immunogenicity score
of epitope NS4A2177–2185 was found to be signiﬁcantly low
i.e. −0.00704. Interestingly, the other two epitopes were found
to be completely conserved among all the polyprotein sequences
included in the study, indicating that they may have potential
evolutionary signiﬁcance.
NS4B2459–2467 was predicted to bind 10 HLA class I alleles
and its antigenicity score was signiﬁcant i.e. 0.7985.
Epitopes NS52592–2600 and NS52520–2528 were predicted to
bind 26 and 12 number of alleles respectively and their antige-
nicity scores were determined to be 0.8097 and 0.5710
respectively. However, the immunogenicity score of NS52592–
2600 was found to be signiﬁcantly low i.e. −0.01296. Epitopes
NS53065–3073, NS52638–2644 and NS52898–2906 were predicted to
bind 7, 8 and 9 alleles respectively and their antigenic scoresand their number of alleles, antigenicity prediction score and immuno-
No. of alleles Antigenicity score Immunogenicity score
7 1.0359 0.14313
10 0.5728 0.35553
10 0.7956 0.23653
11 1.0334 0.12236
7 1.3683 0.10959
13 0.8225 0.23806
13 0.5583 0.18644
12 1.3984 0.01276
11 0.9097 0.21752
10 0.8523 0.13934
14 0.8531 0.08145
9 1.6507 0.26865
6 1.5064 0.0315
20 1.1351 0.244
9 1.2576 −0.00704
7 1.9567 0.05402
8 0.8174 0.5603
10 0.7985 0.29179
12 0.571 0.22198
26 0.8097 −0.01296
8 1.1058 0.41795
9 0.6107 0.2434
7 1.2378 0.19481
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Notably, the immunogenic score of epitope NS52638–2644 was
found to be signiﬁcant as compared to other epitopes i.e.
0.41795.
3.2. Prediction of HLA II binding epitopes
By using ProPred, 48 antigenic epitopes for HLA class II
were predicted in the consensus polyprotein sequence of Zika
virus (Table 2). Epitopes were found to be conserved among the
sequences to a large extent.
Epitope C91–100 was predicted to bind to 9 HLA class II al-
leles and its antigenicity score was found to be signiﬁcantly high
i.e. 0.6639.
It was predicted that prM158–166 will bind with 22 HLA class
II alleles and its antigenicity score was found to be high i.e.Table 2
T-cell class II MHC-speciﬁc predicted epitopes of the Zika virus polyprotein
Part of polyprotein aa position Epitope se
Protein C 91 MLRIINARKE
prM 158 IQIMDLGHM
Envelope protein 403 LVTCAKFAC
470 LGGFGSLGL
545 VVVLGSQEG
588 LRLKGVSYS
676 YIVIGVGEK
764 WLGLNTKNG
765 LGLNTKNGS
NS1 878 VQLTVVVGS
878 VQLTVVVGSVKNPM
965 VREDYSLEC
982 VKGKEAVHS
1004 WRLKRAHLI
1045 LSHHNTREG
1124 WYGMEIRPR
NS2A 1157 LGVLVILLMVQEG
1178 IIISTSMAV
1241 FRANWTPRE
1282 WLAIRAMVVPRT
1285 IRAMVVPRT
1326 FMLLSLKGK
1343 FVMALGLTAVRLVDP
Serine protease NS2B 1383 VGLICALAG
1411 IVSYVVSGK
Serine protease NS3 1597 VQLLAVPPG
1663 YVSAITQGR
1722 VILAPTRVV
1762 LMCHATFTS
2034 FVELMKRGD
2046 WLAYQVASA
NS4A 2174 IMLLGLLGT
2185 LGIFFVLMRNKGIGKM
2202 FGMVTLGAS
2229 IVVFLLLVVLIP
NS4B 2331 YNNYSLMAM
2364 LLMIGCYSQ
2442 VLLIAVAVSS
2496 FRGSYLAGA
NS5 2536 LNQMSALEF
2701 IKVLCPYTS
2750 IKSVSTTSQ
2924 VRSNAALGA
2973 YNMMGKREK
3159 LRRSEKVTN
3238 LHLKDGRSI
3286 LLYFHRRDLRLMANA
3372 LIGHRPRTT1.6065. Epitope prM158–166 has been identiﬁed as an important
epitope in the prM region of the consensus sequence.
Seven important promiscuous HLA class II binding epitopes
were detected in the envelope of the consensus sequence. E403–
411 was predicted to bind 25 HLA II alleles and its antigenic
score was found to be 1.2397. It was predicted that E764–772 will
bind 10 alleles but its antigenic score was signiﬁcantly high as
compared to E403–411 i.e. 2.6277.
NS11004–1012 was predicted to bind 21 HLA class II alleles
and its antigenic score was found to be 1.0216. NS11124–1132
and NS1965–973 were predicted to bind 12 and 11 alleles but their
antigenic score were found to be 2.4357 and 1.6908,
respectively.
Seven important promiscuous HLA II binding epitopes were
detected in the NS2A of the consensus sequence. It was pre-
dicted that NS2A1157–1169 will bind 25 HLA II alleles and itsand their number of alleles and antigenicity prediction score.
quence No. of alleles Antigenicity score
9 0.6639
22 1.6065
25 1.2397
11 2.0219
17 1.1365
19 1.5390
13 2.0591
10 2.6277
14 2.0667
17 0.7907
13 0.5533
11 1.6908
16 0.9250
21 1.0216
10 1.0129
12 2.4357
25 0.6307
17 0.5011
11 2.7633
11 0.8872
14 0.9024
10 2.0071
INVVGLLLLTRSGK 10 1.1286
14 0.9110
11 1.0866
34 0.5392
13 1.1295
18 0.6400
25 0.6299
10 1.1065
13 0.6893
17 1.0058
23 0.7587
13 1.0230
12 0.5274
14 0.9352
22 1.0663
26 0.5388
14 0.6322
18 1.0863
26 0.7501
13 0.8471
28 1.1428
23 1.0356
13 1.0871
13 1.2828
ICSS 12 0.7456
12 1.5275
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were predicted to bind 11 and 10 alleles but their antigenic score
were found to be 2.7633 and 2.0071, comparatively. Out of the
seven promiscuous epitopes identiﬁed in NS2A region, none
was completely conserved among all the polyprotein sequences.
NS2B1383–1391 and NS2B1411–1419 were predicted to bind 14
and 12 HLA class II alleles but their antigenic score was found
to be 0.9110 and 1.0866 respectively. Moreover, both epitopes
were completely conserved among all the polyprotein sequences
included in the study.
It was predicted that NS31597–1605 and NS31762–1770 will bind
34 and 25 HLA class II alleles and their antigenic scores were
determined to be 0.5392 and 0.6299 respectively. Moreover,
both NS31597–1605 and NS31762–1770 were conserved in all the 54
polyprotein sequences of our study. NS31663–1671 and NS32034–
2042 were predicted to bind 13 and 10 HLA II alleles but their
antigenic scores were found to be 1.1295 and 1.1065
respectively.
NS4A2185–2200 was predicted to bind 23 alleles while its
antigenic score was found to be 0.7587. NS4A2174–2182 was
predicted to bind to 17 HLA class II alleles while its antigenic
score was found to be 1.0058. Moreover, this epitope was
conserved in all the polyproteins included in the study.
NS4B2364–2372 was predicted to bind 22 HLA class II alleles
and its antigenic score was found to be 1.0663. NS4B2442–2451
was predicted to bind 26 alleles but its antigenic score was less
comparatively i.e. 0.5388.
NS52924–2932 and NS52701–2709 were predicted to bind 28 and
26 HLA class II alleles and their antigenic scores were deter-
mined to be 1.1428 and 0.7501, respectively. In comparison,
NS53372–3380 and NS53238–3246 were predicted to bind 12 and 13
alleles while their antigenic scores were found to be 1.5275 and
1.2828, respectively. Remarkably, NS52924–2932 epitope was
found to be conserved among all the 54 polyprotein sequences
included in our study.
Moreover it was concluded that none of the epitopes pre-
dicted in this study have been studied previously.
4. Discussion
Zika virus is mainly spread by the Aedes aegypti mosquito,
and has been lately making its presence known throughout
Central America and Latin America, but there are chances that it
might spread to tropical and subtropical regions too [28].
Currently there is no FDA approved vaccine. Even more, there
is no speciﬁc treatment apart from the recommended use of
aspirin and acetaminophen to counteract the fever and muscle
pain and preventive measures against mosquito bites [29].
The Genus Flavivirus consists of diverse and complex group
of pathogens which are antigenically related. The genomes of
these viruses comprise of total 10 proteins and the role of each of
the protein in viral pathogenesis is not yet completely elucidated.
Effective immunization treatment for some members exists
while due to some immunobiology complexities, vaccines for
other members are still to be made. Most of animal models are
either immune to ﬂavivirus or they do not completely represent
all manifestations of disease. Some human data of Flavivirus do
exist; however, it does not represent all forms of disease and its
global variation in populations [30].
Epitope based vaccines are already showing hopeful results.
This promising vaccine technology has allowed for the pre-
vention and treatment of cancer, viral, bacterial and otherdiseases [31–36]. Numerous immune-bioinformatics methods and
tools have now been developed to assist in the search for T-cell
MHC binding epitopes. Design and development of a vaccine
using T cell speciﬁc epitopes is considerably more favourable
because they evoke a long-term immune response and dodge
antigenic drift whereas antigen can effortlessly evade the anti-
body memory response [21]. Both the CD4+ and CD8+ T cells
have essential role in antiviral immune response as well as
clonal expansion of B cell. In this study, we used the full-
length polyprotein sequence of the Zika virus in order to in-
crease the coverage of the genome and to search for promiscu-
ous epitopes in both the structural and non-structural proteins of
this virus. At the time of writing, no Zika virus T or B-cell
epitopes have been uploaded to the Immune Epitope Database
Analysis Resource (IEDB); a manually curated repository of
experimentally characterized immune epitopes. The IEDB can
be used by scientists to help in the identiﬁcation, characteriza-
tion, mapping and evaluation of likely targets for vaccine,
therapeutic and diagnostic nominees, and moreover to give us a
broader knowledge of the pathogenesis and immunobiology of
any new disease or epidemic. The current study is a ﬁrst attempt
which intended to screen novel and highly probable immuno-
genic epitopes for T cells across all the major proteins of ZIKV.
Furthermore, these crucial data can be uniﬁed with data from
supplementary databases (Pharmacogenomics, genomic, prote-
omic, or genomic), in doing so increasing the usefulness and
wide-ranging scope of the analyses.
In our study, a greater number of epitopes were projected for
MHC class II when compared to MHC class I. The results of this
study are in conformity with a meta-analysis study that
enumerated a greater number of Class II epitopes in the Flavi-
virus genus [37]. Out of 23 identiﬁed MHC 1 binding antigenic
epitopes, 12 epitopes i.e. E462–470, E640–648, NS11059–1067,
NS2A1156–1164, NS2A1355–1363, NS2B1381–1389, NS31622–1630,
NS31688–1696, NS32018–2026, NS4A2177–2185, NS4A2220–2238 and
NS52520–2528, were completely conserved in intact form among
all the polyprotein sequences included in the study. Epitope
E640–648 was predicted to bind to 11 HLA class I alleles and
its antigenicity score was signiﬁcant i.e. 1.0334. Moreover, its
sequence was completely conserved in all the polyprotein
sequences included in our study. Hence, E640–648 was
identiﬁed as the best envelope HLA 1 epitope in our study.
Epitopes NS32018–2026 was predicted to bind 20 HLA Class 1
alleles and its antigenicity score were found out to be 1.1351.
Amazingly, it was found to be completely conserved among
all the polyprotein sequences included in our study, indicating
that these epitopes can be important for developing universally
applicable vaccines. Notably, the immunogenicity score of
NS4A2220–2238 was found to be the highest (i.e. 0.5603)
among all the HLA class I binding epitopes determined in our
study.
Out of 48 predicted HLA II epitopes, 18 epitopes were found
to be completely conserved in all of the polyprotein sequences
included in the study. These epitopes are C92–99, E470–478, E588–
596, NS1878–886, NS1878–891, NS11124–1132, NS2B1383–1391,
NS2B1411–1419, NS31597–1605, NS31762–1770, NS32046–2054,
NS4A2174–2182, NS4A2229–2240, NS4B2331–2339, NS4B2496–2504,
NS52536–2544, NS52750–2758 and NS52924–2932. Notably, the
antigenic epitope NS31597–1605 has been predicted to bind 34 out
of 51 HLA class II alleles. Epitope C92–99 was predicted to bind
to 25 HLA class II alleles and its antigenicity score was found to
be signiﬁcantly high i.e. 1.8011. Moreover, as discussed, this
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polyprotein sequences included in our study. This indicates that
this epitope can serve as an important part of universally
applicable vaccines. NS11124–1132 was completely conserved
among all the polyprotein sequences, indicating that this epitope
can be useful for developing a universally applicable vaccine,
especially considering its signiﬁcant antigenic prediction.
Structures of all ten of ﬂavivirus genus viral proteins are
reported, though complete data of all the 10 proteins for a single
virus have not been reported yet. The best overall epitope dis-
tribution is available for WNV and DENV (ten out of ten for
both) and the highest number of epitopes for the whole genus
have been obtained from NS3 and E proteins. The human
epitope data collected from the patients of Japanese encephalitis,
dengue hemorrhagic fever, dengue fever, yellow fever and West
Nile fever indicates the presence of both B-cell and T-cell epi-
topes. [37].
According to a 2010 Meta-analysis study of all immune data
in the Flavivirus genus [37], 1200 epitopes were identiﬁed in that
study and most of the epitopes belonged to the dengue virus
group followed by WNV and YFW. The higher percentage of
epitopes identiﬁed for dengue virus, WNV and YFW indicate
their worldwide impact on mortality and morbidity in human
population while smaller number of epitopes recognized for
other viruses indicates the presence of established prophylaxes
or their less dreadful impact on human population. All the
epitopes reported up to date are peptidic in nature and there is
objectively even scattering of B-cell and T-cell epitopes in the
genus as a whole. T-cell epitopes have been recognized in six
out of nine ﬂavivirus and the largest numbers of T-cell
epitopes reported are in WNV DENV and YFW. Both CD4
and CD8 epitopes are deﬁned for ﬂavivirus but it was
observed that DENV viruses have predominantly CD8+ T-cell
epitopes while other viruses (WNV and JEV) mostly have
CD4 T-cell epitopes.
Not surprisingly the data on host distribution of epitope
reactivity's indicates that most of the ﬂavivirus epitopes are
deﬁned in either humans or mice. A large number of DENV
epitopes were deﬁned in humans, as expected but surprisingly
very low numbers of epitopes for WNV, YFW and complete
absence of epitopes for JEV. Speculation is that low number of
epitopes for JEV is due to availability of JEV vaccine. Identi-
ﬁcation of epitopes in NHP still remains of great interest despite
the fact that they are quite expensive and have limited avail-
ability but they can be used as natural hosts and have biological
and immunological similarities with humans [37,38].
Due to lack of a suitable animal model, very small numbers
of protective epitopes are reported for ﬂavivirus: DENV, JEV,
and TBEV [37–41]. Many animal models are used to study
diverse characteristics of ﬂavivirus infection but, the standard
model used is murine model. Although mice natural resistance
to infection caused by certain ﬂavivirus is problematic as it
causes hindrance in measuring protective immunity of animal,
Humanized or susceptible mouse models are being developed
which can mimic disease symptoms more closely related to
humans. However, until then we mostly have to rely on
extrapolation of clinical studies [37,42].
A large number of epitopes (both larger and smaller) are
identiﬁed in humans for the period of the natural course of
infection for Dengue, West Nile, and Japanese Encephalitis vi-
ruses respectively. However, the numbers of epitopes were
higher for DENV [37]. The contemporary data available is,however, inadequate and cannot provide a solution to the
questions related to the immunopathological aspects of these
viruses. However, we can extrapolate the epitope ﬁndings of
other members of the Flavivirus genus to the ZIKV [43,44].
One downside of our study is the lack of in vitro and in vivo
studies to test whether these peptidic epitopes will elicit a strong
and protective immune response in humans. Since these epitopes
were predicted using an in-silico approach, experimental studies
are a must before such epitopes are used in vaccine formulations.
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